Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys

Experimental Neurology

Volumn 183, Issue 2, 2003, Pages 418-429

  Eslamboli, Andisheh ^a   Baker, Harry F ^c   Ridley, Rosalind M ^a   Annett, Lucy E ^b  

^a Dept of Experimental Psychology ^*  (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c School of Veterinary Medicine   (United Kingdom)

Author keywords

6 Hydroxydopamine; Accumbens; Basal ganglia; Caudate; Dopamine; Marmoset; Monkey; Parkinson's disease; Putamen; Substantia nigra

Indexed keywords

METIROSINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CELL COUNT; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MARMOSET; NONHUMAN; PARKINSON DISEASE; PLANNING; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; SENSORIMOTOR NEUROPATHY; SUBSTANTIA NIGRA;

EID: 0141449053     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00139-0     Document Type: Article

References (59)

1. Annett L.E., Rogers D.C., Hernandez T.D., Dunnett S.B. Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain. 115:1992;825-856.
2. Barneoud P., Descombris E., Aubin N., Abrous D.N. Evaluation of simple and complex sensorimotor behaviours in rats with a partial lesion of the dopaminergic nigrostriatal system. Eur. J. Neurosci. 12:2000;322-336.
3. Beck K.D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R.A., Rosenthal A., Hefti F. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature. 373:1995;339-341.
4. Bjorklund A., Lindvall O. Parkinson disease gene therapy moves toward the clinic. Nat. Med. 6:2000;1207-1208.
5. Bjorklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4:1997;186-200.
6. Blanchet S., Marie R.M., Dauvillier F., Landeau B., Benali K., Eustache F., Chavoix C. Cognitive processes involved in delayed non-matching-to-sample performance in Parkinson's disease. Eur. J. Neurol. 7:2000;473-483.
7. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., Kupsch A., Crabb L., Odin P., Gustavii B., Bjorklund A., Brooks D.J., Marsden C.D., Oertel W.H., Quinn N.P., Rehncrona S., Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain. 123:2000;1380-1390.
8. Chio A., Magnani C., Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy comparison of tracer methodology and clinical ascertainment of cases . Mov. Disord. 13:1998;400-405.
9. Connor B., Kozlowski D.A., Unnerstall J.R., Elsworth J.D., Tillerson J.L., Schallert T., Bohn M.C. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp. Neurol. 169:2001;83-95.
10. Costa S., Iravani M.M., Pearce R.K., Jenner P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur. J. Pharmacol. 412:2001;45-50.
11. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 122:1999;1437-1448.
12. Diamond A., Goldman-Rakic P. Evidence for involvement of prefrontal cortex in cognitive changes during the first year of life comparison of performance of human infants and rhesus monkeys on a detour task with transparent barrier . Soc. Neurosci. Abs. 11:1985;832-832.
13. Diamond A., Zola-Morgan S., Squire L.R. Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants. Behav. Neurosci. 103:1989;526-537.
14. Durif F., Lemaire J.J., Debilly B., Dordain G. Acute and chronic effects of anteromedial globus pallidus stimulation in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 67:1999;315-322.
15. Errea J.M., Ara J.R., Aibar C., de-Pedro-Cuesta J. Prevalence of Parkinson's disease in lower Aragon, Spain. Mov. Disord. 14:1999;596-604.
16. Fahn S. An overview of novel therapies for Parkinson's disease. Exp. Neurol. 144:1997;21-23.
17. Finkelstein D.I., Stanic D., Parish C.L., Tomas D., Dickson K., Horne M.K. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience. 97:2000;99-112.
18. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 380:1996;252-255.
19. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56:1999;33-39.
20. Gerhardt G.A., Cass W.A., Huettl P., Brock S., Zhang Z., Gash D.M. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res. 817:1999;163-171.
21. Gundersen H.J.C., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147:1987;229-263.
22. Hagell P., Schrag A., Piccini P., Jahanshahi M., Brown R., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Odin P., Wenning G.K., Morrish P., Gustavii B., Bjorklund A., Brooks D.J., Marsden C.D., Quinn N.P., Lindvall O. Sequential bilateral transplantation in Parkinson's disease effects of the second graft . Brain. 122:1999;1121-1132.
23. Henderson J.M., Annett L.E., Torres E.M., Dunnett S.B. Behavioral effects of subthalamic nucleus lesions in the hemiparkinsonian marmoset (Callithrix jacchus). Eur. J. Neurosci. 10:1998;689-698.
24. Hirsch E.C., Graybiel A.M., Agid Y. Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease. Acta Neurol. Scand. Suppl. 126:1989;19-22.
25. Kawamoto Y., Nakamura S., Matsuo A., Akiguchi I., Shibasaki H. Immunohistochemical localization of glial cell line-derived neurotrophic factor in the human central nervous system. Neuroscience. 100:2000;701-712.
26. Kendall A.L., David F., Rayment G., Torres E.M., Annett L.E., Dunnett S.B. The influence of excitotoxic basal ganglia lesions on motor performance in the common marmoset. Brain. 123:2000;1442-1458.
27. Kirik D., Georgievska B., Rosenblad C., Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur. J. Neurosci. 13:2001;1589-1599.
28. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152:1998;259-277.
29. Kirik D., Rosenblad C., Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 12:2000;3871-3882.
30. Kirik D., Rosenblad C., Bjorklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system . J. Neurosci. 20:2000;4686-4700.
31. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
32. Lapchak P.A., Gash D.M., Jiao S., Miller P.J., Hilt D. Glial cell line-derived neurotrophic factor a novel therapeutic approach to treat motor dysfunction in Parkinson's disease . Exp. Neurol. 144:1997;29-34.
33. Lee C.S., Sauer H., Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience. 72:1996;641-653.
34. MacDonald B.K., Cockerell O.C., Sander J.W., Shorvon S.D. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 123:2000;665-676.
35. Mandel R.J., Snyder R.O., Leff S.E. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp. Neurol. 160:1999;205-214.
36. Miklyaeva E.I., Castaneda E., Whishaw I.Q. Skilled reaching deficits in unilateral dopamine-depleted rats impairments in movement and posture and compensatory adjustments . J. Neurosci. 14:1994;7148-7158.
37. Montoya C.P., Astell S., Dunnett S.B. Effects of nigral and striatal grafts on skilled forelimb use in the rat. Prog. Brain Res. 82:1990;459-466.
38. Montoya C.P., Campbell-Hope L.J., Pemberton K.D., Dunnett S.B. The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats . J. Neurosci. Methods. 36:1991;219-228.
39. Nosrat C.A., Tomac A., Lindqvist E., Lindskog S., Humpel C., Stromberg I., Ebendal T., Hoffer B.J., Olson L. Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system. Cell Tissue Res. 286:1996;191-207.
40. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test . J. Neurosci. 15:1995;3863-3875.
41. Owen A.M., Iddon J.L., Hodges J.R., Summers B.A., Robbins T.W. Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia. 35:1997;519-532.
42. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 67:1995;631-647.
43. Rascol O., Brooks D.J., Korczyn A.D., De-Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342:2000;1484-1491.
44. Ridley R.M., Baker H.F., Crow T.J. Behavioral effects of amphetamines and related stimulants the importance of species differences as demonstrated by a study in the marmoset . Caldwell J. Amphetamine and Related Stimulants Chemical, Biological, Clinical, and Sociological Aspects . 1980;97-116 CRC Press, Boca Raton, FL.
45. Rodter A., Winkler C., Samii M., Nikkhah G. Complex sensorimotor behavioral changes after terminal striatal 6-OHDA lesion and transplantation of dopaminergic embryonic micrografts. Cell Transplant. 9:2000;197-214.
46. Roedter A., Winkler C., Samii M., Walter G.F., Brandis A., Nikkhah G. Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions evidence for interhemispheric functional coupling of the two nigrostriatal pathways . J. Comp. Neurol. 432:2001;217-229.
47. Rosenblad C., Kirik D., Bjorklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 161:2000;503-516.
48. Rosenblad C., Martinez-Serrano A., Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience. 82:1998;129-137.
49. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine a combined retrograde tracing and immunocytochemical study in the rat . Neuroscience. 59:1994;401-415.
50. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50:1996;275-331.
51. Stephan H., Baron G., Schwerdtfeger W.K. The Brain of the Common Marmoset (Callithrix jacchus) A Stereotaxic Atlas . 1980;Springer-Verlag, Berlin.
52. Stern M.B., Freese A. Parkinson's disease the case for novel treatment strategies . Exp. Neurol. 144:1997;2-3.
53. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R., Redmond D.E. Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys. Brain. 113:1990;617-637.
54. Taylor J.R., Roth R.H. Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP long-term performance and effect of transparency of the barrier . Behav. Neurosci. 104:1990;564-576.
55. Tseng J.L., Baetge E.E., Zurn A.D., Aebischer P. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17:1997;325-333.
56. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231:1991;482-497.
57. Winkler C., Sauer H., Lee C.S., Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16:1996;7206-7215.
58. Zhang Z., Miyoshi Y., Lapchak P.A., Collins F., Hilt D., Lebel C., Kryscio R., Gash D.M. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J. Pharmacol. Exp. Ther. 282:1997;1396-1401.
59. Zigmond M.J., Acheson A.L., Stachowiak M.K., Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 41:1984;856-861.